E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Advanced Melanoma |
melanoma avanzato |
|
E.1.1.1 | Medical condition in easily understood language |
Advanced Melanoma |
melanoma avanzato |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10027481 |
E.1.2 | Term | Metastatic melanoma |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The purpose of the study is to compare the 18-month overall survival rate in subjects with advanced melanoma receiving ipilimumab monotherapy (3 mg/kg) as retreatment versus chemotherapy of investigator’s choice in subjects who are randomized at the time of ipilimumab retreatment eligibility. This comparison will be done after the last randomized subject had the chance to be followed for 18 months. |
L’obiettivo principale dello studio è quello di confrontare il tasso di sopravvivenza complessiva a 18 mesi in soggetti con melanoma avanzato che stanno ricevendo ipilimumab in monoterapia (3 mg/Kg) come ritrattamento rispetto alla chemioterapia a scelta dell’investigatore in soggetti che vengono randomizzati nel momento in cui risultano eligibili per il ritrattamento con ipilimumab. Questo confronto verrà analizzato dopo che l’ultimo soggetto randomizzato ha avuto la possibilità di essere seguito per 18 mesi. |
|
E.2.2 | Secondary objectives of the trial |
To compare overall survival between retreatment with ipilimumab versus chemotherapy of investigator’s choice.-To compare best overall response rate (BORR by mWHO criteria) between retreatment with ipilimumab versus chemotherapy of investigator’s choice. - To compare Progression free survival (PFS by mWHO criteria) between retreatment with ipilimumab versus chemotherapy of investigator’s choice. - To assess the EORTC-QLQ-C30 between retreatment with ipilimumab versus chemotherapy of investigator’s choice |
- Confrontare la sopravvivenza complessiva tra il ritrattamento con Ipilimumab e la chemioterapia a discrezione dell’investigatore - Confrontare la percentuale della migiore risposta complessiva (BORR tramite i criteri mWHO) tra il ritrattamento con Ipilimumab rispetto alla chemioterapia a discrezione dell’investigatore - Confrontare la sopravvivenza libera da progressione (PFS tramite i criteri mWHO) tra il ritrattamento con Ipilimumab rispetto alla chemioterapia a discrezione dell’investigatore - Valutare lo stato di salute complessivo rispetto alla qualità di vita in base all’ European Organisation for Research and Treatment of Care (EORTC) QLQ-C30 tra il ritrattamento con Ipilimumab rispetto alla chemioterapia a discrezione dell’investigatore. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Histological diagnosis of unresectable stage III or IV metastatic melanoma - Prior ipilimumab induction treatment (3mg/kg) - Documented disease control (SD ≥ 3 months or PR/CR) after ipilimumab Induction - Documented progressive disease following disease control |
-Diagnosi istologica di Melanoma Metastatico o non operabile di Stadio III o IV; -Precedente trattamento di induzione con Ipilimumab (3mg/kg) -Controllo della malattia documentato (Stabilità SD > 3 mesi o Risposta Parziale o Completa PR/CR) dopo induzione con Ipilimumab -Progressione di malattia documentata dopo iniziale controllo di malattia |
|
E.4 | Principal exclusion criteria |
- Subjects with brain metastasis are excluded, unless they are free of neurologic symptoms related to metastatic brain lesions and do not receive systemic corticosteroid therapy for the purpose of reducing intracranial inflammation in the 10 days prior to beginning retreatment with ipilimumab. - Any intervening anticancer therapy between last dose of ipilimumab induction and ipilimumab retreatment on study -Subjects who experienced any grade 3 irAE (except for endocrinopathies where clinical symptoms were controlled with appropriate hormone replacement therapy) or any grade 4 toxicity during prior treatment with ipilimumab. -Subjects with a prior irAE that has not improved to grade 1 or better atrandomization. |
-Soggetti con metastasi cerebrali sono esclusi, a meno che non siano privi di sintomi neurologici legati alle lesioni cerebrali metastatiche e che non ricevono terapia con corticosteroidi sistemici per ridurre l’infiammazione intracranica nei 10 giorni precedenti l’inizio del ritrattamento con Ipilimumab. - Qualsiasi terapia anticancro effettuata tra l’ultima dose di induzione con Ipilimumab e l’inizio del ritrattamento con Ipilimumab nell’ambito dello studio - Soggetti che hanno avuto Eventi Avversi Immuno-Correlati (irAE) di Grado 3 (eccetto le endocrinopatie in cui i sintomi clinici erano controllati con appropriate terapie di sostituzione ormonale) o tossicità di Grado 4 durante il precedente trattamento con ipilimumab -Soggetti con precedenti Eventi Avversi Immuno-Correlati (irAE) che non sono migliorati al Grado 1 o risolti al momento della randomizzazione |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Overall survival rate at 18 months from LPFV |
Tasso di sopravvivenza complessiva a 18 mesi dalla LPFV. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Vital status will be assessed at each study visit. Analysis of overall survival rate will be done at 18 months from LPFV. |
Lo stato di sopravvivenza verrà valutato ad ogni visita dello studio. L’analisi del tasso di sopravvivenza complessiva verrà effettuata a 18 mesi dal LPFV. |
|
E.5.2 | Secondary end point(s) |
1. Overall survival. 2. Progression Free Survival 3. Best Overall Response Rate. 4. Assessment of EORTC QLQ-C30 |
1. Sopravvivenza complessiva 2. Sopravvivenza libera da progressione 3. Percentuale della migliore risposta complessiva 4. Valutazione dello stato di salute complessivo rispetto alla qualità di vita (EORTC QLQ-C30) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Every study visit (q3months until 18 months, then q6months) 2. Every study visit (q3months until 18 months, then q6months) 3. Every three months (as of Month 3) until Month 18, and every 6 months thereafter. 4. At Baseline (week 1 prior to first dose), during treatment (every 6 weeks, always prior to dosing), at end of treatment, and at all visits thereafter |
1. Ad ogni visita dello studio (ogni 3 mesi fino al mese 18, successivamente ogni 6 mesi) 2. Ad ogni visita dello studio (ogni 3 mesi fino al mese 18, successivamente ogni 6 mesi) 3. Ogni 3 mesi (a partire dal Mese 3) fino al Mese 18, e successivamente ogni 6 mesi 4. Al baseline (Settimana 1 prima della prima dose), durante il periodo di trattamento (ogni 6 settimane, sempre prima della dose), alla fine del trattamento, e successivamente a tutte le visite. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Biomarker Assessments-Outcomes Research Assessm.-Health Related Resource Utilization (HRRU) Assessm. |
Biomarker Assessments-Outcomes Research Assessm.-Health Related Resource Utilization (HRRU) Assessm. |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 30 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study will remain open until the last subject randomized has been followed for 5 years or the study is terminated by the sponsor. Subjects who discontinue study drug therapy early - due to disease progression or study drug intolerance or for any other reason - will continue to be followed up for survival for 5 years after randomization. |
Studio aperto fino a che l'ultimo soggetto randomizzato sia stato seguito x 5 anni o fino a interruzione studio da parte sponsor. Sogget.che hanno interrotto prima la terapia in studio saranno seguiti x per sopravvivenza x 5 anni dopo randomizzaz |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 73 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 73 |
E.8.9.2 | In all countries concerned by the trial days | 0 |